Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Deadly Drug-Resistant Strain of Escherichia coli Emerged as a Single Genetic Clone

By BiotechDaily International staff writers
Posted on 02 Jan 2014
Image: Colonies of Escherichia coli growing in a laboratory culture (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Image: Colonies of Escherichia coli growing in a laboratory culture (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Molecular microbiologists working with advanced genomic research tools have shown that an extremely virulent and drug-resistant strain of Escherichia coli appeared about 10 years ago following mutations in two genes.

Previous studies on the H30-Rx clone of the ST131 strain of E. coli using pulsed-field gel electrophoresis (PFGE) had indicated that characteristics such as propensity for extraintestinal infections, fluoroquinolone resistance, and extended-spectrum beta-lactamase (ESBL) production had arisen as a series of independent genetic events. If this conclusion were correct, it would suggest that the existence of many different intermediate strains would exist with multiple pathways for evading the immune system and medical treatment.

However, in a new study published in the December 17, 2013, edition of the journal mBio, investigators at George Washington University School of Public Health (Washington DC, USA) and their colleagues at the University of Minnesota (Minneapolis, USA) used the advanced genomic technique, whole-genome sequencing, to reconstruct the evolutionary history of the ST131 clone. The investigators analyzed the genomes of samples of E. coli collected from patients and animals in five countries over the 44-year period, 1967–2011.

They found that fluoroquinolone resistance was confined almost entirely to a single, rapidly expanding ST131 subclone, designated H30-R. This clone, which was fully resistant to the drug ciprofloxacin, soon morphed into a new clone called H30-Rx, which was resistant to several extended-spectrum antibiotics, such as third-generation cephalosporins.

The investigators believe that the clonal nature of H30-Rx may provide opportunities for vaccine or transmission prevention-based control strategies, which could gain importance as H30-Rx and other extraintestinal pathogenic E. coli subclones become resistant to an increasing number of antibiotics.

"This strain of E. coli spreads from person to person and seems to be particularly virulent," said contributing author Dr. James R. Johnson, professor of medicine at the University of Minnesota. "This study might help us develop better tools to identify, stop or prevent its spread by finding better ways to block the transmission of the superbug, or by finding a diagnostic test that would help doctors identify such an infection early on, before it might have the chance to turn lethal."

Related Links:

George Washington University School of Public Health
University of Minnesota



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.